Restoring p53 function may therefore provide an attractive therapeutic strategy to target cancer cells and thus, small molecules such as the MDM2 antagonist Nutlin-3 [23], the p53-binding molecule RITA [24], and the MDM2 down-regulator gambogic acid [25], have been developed. This evidence concerns the gene TP53 and cancer.